The VICC.ORG Directory of Cancers: Treatments, Services & Resources

Skin Cancers and Melanoma

The melanoma program comprises of a diverse group of clinical and laboratory scientists with one common goal: Advancement of the treatment of melanoma.


Clinical Trials for Skin Cancers and Melanoma

13 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
Basic ScienceVICCMEL09109
06/03/2010
Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy
Basic ScienceVICCMEL0287
05/06/2003
Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository
OtherVICCMEL12117
02/18/2013
A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy
TreatmentVICCMELP1388
03/24/2014
A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors.
TreatmentVICCMEL1351
10/17/2013
A Phase 2 study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
TreatmentVICCMELP1325
09/25/2013
A Phase IB/II, Multicenter, Study of LEE011 in Combination with LGX818 in Adult Patients with BRAF mutant melanoma
TreatmentVICCPHI1333
09/18/2013
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination with GSK2141795
TreatmentVICCPHI1328
09/05/2013
A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination with Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma
TreatmentVICCMEL1263
01/08/2013
Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma
TreatmentVICCMEL1256
12/06/2012
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence
TreatmentVICCPHI1231
11/19/2012
Phase 1/2 Study of PI-3K Inhibition with PX-866 Combined with Vemurafenib (BRAF Inhibitor) in Patients with BRAF-Mutant Cancer Including Advanced Melanoma
TreatmentVICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
TreatmentVICCMEL0759
08/01/2008
A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma

You do not have JavaScript enabled. This site works better with JavaScript turned on.